Treatment of spasticity and dyston?a in PCI with Botulinum toxin A. BACKGROUND: Botulinum-A (NxTxBoA) toxin produce neuromuscular blockade, it has been effective with therapeutic purposes in strabismus, focal dystonias and spasticity. OBJECTIVE: Evaluate the therapeutically effects off NxTxBoA in cerebral palsy (CP) spastic and/or dystonic in children. Prospective study. MATERIAL AND METHODS: 12 CP patients (8 spastic and 4 spastic/dystonic) were treated with NxTxBoA in affected muscles at least for 2 doses by up 12 months. The indication was: improve limb function, to avoid surgical correction or improve hygienic or dressing. Ashworth Spasticity Scale (ASS), functional scale for Dystonic Sindou-Millet (SMS) and O'Brien Global Assessment Scale (OGAS) were used to evaluate improvement. STATISTICAL METHODS: No parametric tests, Wilcoxon's rang's test and sign test were used with p < 0.05. RESULTS: Total doses session was 3-10 U/kg. AAS showed muscle spasticity improvement in two grades in 8 patients, and one grade in the rest (p = 0.004). SMS showed the muscle dystonic improve up 60\% in two patients improve 50\% in others (p = 0.006). OGAS demonstrated a good correlation. Mean treatment effect during 4.8 months (rank 4 to 10 m). Two patients had side effects, general weakness, instability, and focal haematoma. CONCLUSIONS: Botulinum toxin type A proved a highly useful adjuvant therapy and conservative management in CP.
%0 Journal Article
%1 Aguilar-Rebolledo2001
%A Aguilar-Rebolledo, F.
%A Hern?ndez-S?nchez, J.
%A Rayo-Mares, D.
%A Soriano-Fonseca, F.
%A Garc?a-Mu?oz, L.
%A Ruiz-Ponce, J.
%A Garrido-Ram?rez, E.
%D 2001
%J Gac Med Mex
%K Adolescent; Adult; Botulinum Toxin Type A; Cerebral Palsy; Child; Child, Preschool; Dystonia; Humans; Muscle Spasticity; Neuromuscular Agents; Prospective Studies
%N 5
%P 403--411
%T Botulin toxin as treatment for spasticity and dystonia in infantile cerebral paralysis
%V 137
%X Treatment of spasticity and dyston?a in PCI with Botulinum toxin A. BACKGROUND: Botulinum-A (NxTxBoA) toxin produce neuromuscular blockade, it has been effective with therapeutic purposes in strabismus, focal dystonias and spasticity. OBJECTIVE: Evaluate the therapeutically effects off NxTxBoA in cerebral palsy (CP) spastic and/or dystonic in children. Prospective study. MATERIAL AND METHODS: 12 CP patients (8 spastic and 4 spastic/dystonic) were treated with NxTxBoA in affected muscles at least for 2 doses by up 12 months. The indication was: improve limb function, to avoid surgical correction or improve hygienic or dressing. Ashworth Spasticity Scale (ASS), functional scale for Dystonic Sindou-Millet (SMS) and O'Brien Global Assessment Scale (OGAS) were used to evaluate improvement. STATISTICAL METHODS: No parametric tests, Wilcoxon's rang's test and sign test were used with p < 0.05. RESULTS: Total doses session was 3-10 U/kg. AAS showed muscle spasticity improvement in two grades in 8 patients, and one grade in the rest (p = 0.004). SMS showed the muscle dystonic improve up 60\% in two patients improve 50\% in others (p = 0.006). OGAS demonstrated a good correlation. Mean treatment effect during 4.8 months (rank 4 to 10 m). Two patients had side effects, general weakness, instability, and focal haematoma. CONCLUSIONS: Botulinum toxin type A proved a highly useful adjuvant therapy and conservative management in CP.
@article{Aguilar-Rebolledo2001,
abstract = {Treatment of spasticity and dyston?a in PCI with Botulinum toxin A. BACKGROUND: Botulinum-A (NxTxBoA) toxin produce neuromuscular blockade, it has been effective with therapeutic purposes in strabismus, focal dystonias and spasticity. OBJECTIVE: Evaluate the therapeutically effects off NxTxBoA in cerebral palsy (CP) spastic and/or dystonic in children. Prospective study. MATERIAL AND METHODS: 12 CP patients (8 spastic and 4 spastic/dystonic) were treated with NxTxBoA in affected muscles at least for 2 doses by up 12 months. The indication was: improve limb function, to avoid surgical correction or improve hygienic or dressing. Ashworth Spasticity Scale (ASS), functional scale for Dystonic Sindou-Millet (SMS) and O'Brien Global Assessment Scale (OGAS) were used to evaluate improvement. STATISTICAL METHODS: No parametric tests, Wilcoxon's rang's test and sign test were used with p < 0.05. RESULTS: Total doses session was 3-10 U/kg. AAS showed muscle spasticity improvement in two grades in 8 patients, and one grade in the rest (p = 0.004). SMS showed the muscle dystonic improve up 60\% in two patients improve 50\% in others (p = 0.006). OGAS demonstrated a good correlation. Mean treatment effect during 4.8 months (rank 4 to 10 m). Two patients had side effects, general weakness, instability, and focal haematoma. CONCLUSIONS: Botulinum toxin type A proved a highly useful adjuvant therapy and conservative management in CP.},
added-at = {2014-07-19T17:36:44.000+0200},
author = {Aguilar-Rebolledo, F. and Hern?ndez-S?nchez, J. and Rayo-Mares, D. and Soriano-Fonseca, F. and Garc?a-Mu?oz, L. and Ruiz-Ponce, J. and Garrido-Ram?rez, E.},
biburl = {https://www.bibsonomy.org/bibtex/26494e0102f9b11d188e6eba6103355cb/ar0berts},
groups = {public},
interhash = {368ad91ab3dda07c184e8e840e058a6c},
intrahash = {6494e0102f9b11d188e6eba6103355cb},
journal = {Gac Med Mex},
keywords = {Adolescent; Adult; Botulinum Toxin Type A; Cerebral Palsy; Child; Child, Preschool; Dystonia; Humans; Muscle Spasticity; Neuromuscular Agents; Prospective Studies},
number = 5,
pages = {403--411},
pmid = {11692809},
timestamp = {2014-07-19T17:36:44.000+0200},
title = {[Botulin toxin as treatment for spasticity and dystonia in infantile cerebral paralysis]},
username = {ar0berts},
volume = 137,
year = 2001
}